Evaluation of nanoparticle uptake in co-culture cancer models.
Co-culture models are currently bridging the gap between classical cultures and in vivo animal models. Exploring this novel approach unlocks the possibility to mimic the tumor microenvironment in vitro, through the establishment of cancer-stroma synergistic interactions. Notably, these organotypic models offer a perfect platform for the development and pre-clinical evaluation of candidate nanocarriers loaded with anti-tumoral drugs in a high throughput screening mode, with lower costs and absence of ethical issues. However, this evaluation was until now limited to co-culture systems established with precise cell ratios, not addressing the natural cell heterogeneity commonly found in different tumors. Therefore, herein the multifunctional nanocarriers efficiency was characterized in various fibroblast-MCF-7 co-culture systems containing different cell ratios, in order to unravel key design parameters that influence nanocarrier performance and the therapeutic outcome. The successful establishment of the co-culture models was confirmed by the tissue-like distribution of the different cells in culture. Nanoparticles incubation in the various co-culture systems reveals that these nanocarriers possess targeting specificity for cancer cells, indicating their suitability for being used in this illness therapy. Additionally, by using different co-culture ratios, different nanoparticle uptake profiles were obtained. These findings are of crucial importance for the future design and optimization of new drug delivery systems, since their real targeting capacity must be addressed in heterogenous cell populations, such as those found in tumors.
Centro de Investigação em Ciências da Saúde (CICS), Universidade da Beira Interior, Covilhã, Portugal.
Elisabete C
EC
Costa
Vítor M
VM
Gaspar
João G
JG
Marques
Paula
P
Coutinho
Ilídio J
IJ
Correia
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D045744:Cell Line, Tumor; D018920:Coculture Techniques; D004337:Drug Carriers / Q000032:analysis / Q000378:metabolism*; D016503:Drug Delivery Systems; D005347:Fibroblasts / Q000166:cytology; D006801:Humans; D053758:Nanoparticles / Q000032:analysis / Q000378:metabolism*; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism
D000970:Antineoplastic Agents; D004337:Drug Carriers